Guggenheim Downgrades Centessa Pharmaceuticals to Neutral
Centessa Pharmaceuticals +0.23%
Centessa Pharmaceuticals CNTA | 39.57 | +0.23% |
Guggenheim analyst Debjit Chattopadhyay downgrades Centessa Pharmaceuticals (NASDAQ:
CNTA) from Buy to Neutral.
